Company Focus
Lundbeck
Latest Lundbeck News
Latest Lundbeck News
Biotechnology
Danish biopharma company Lundbeck posted a robust 18% revenue increase in the third quarter of 2024, reaching 5.7 billion Danish kroner ($815 million). Earnings per share rose to 0.78 kroner, marking a 15% year-on-year improvement, while adjusted earnings per share increased by 11%. 13 November 2024
Biotechnology
Danish CNS specialist Lundbeck has announced that Vyepti (eptinezumab) met the primary and all key secondary endpoints in SUNRISE, a Phase III pivotal clinical trial predominantly conducted in Asia evaluating the efficacy and safety in patients with chronic migraine. 31 October 2024
Pharmaceutical
Last week’s significant news included Denmark-based CNS drugmaker Lundbeck reaching agreement to acquire US firm Longboard Pharmaceuticals, along with its bexicaserin, for $2.6 billion. Also, US pharma giant Pfizer entered into a deal with TRIANA Biomedicines to develop molecular glue degraders. On the regulatory front, the US Food and Drug Administration (FDA) last week approved Novocure’s key product Optune Lua for lung cancer patients. Also, German biotech BioNTech and its US partner OncoC4 received a partial clinical hold from the FDA on the Phase III trial of gotistobart in lung cancer. The European Medicines Agency’s human health committee, CHMP, Reaffirmed its non-approval of PTC Therapeutic’s Translarna. 20 October 2024
Biotechnology
Danish CNS specialist Lundbeck today revealed that it has reached to acquire Longboard Pharmaceuticals. 15 October 2024
Pharmaceutical
CNS specialist Lundbeck has announced data from the TALISMAN natural history study, as well as additional data from the AMULET trial, of amlenetug, in multiple system atrophy (MSA) at the International Congress of Parkinson's Disease and Movement disorders in Philadelphia, USA. 27 September 2024
Latest CNS News & Features
Latest CNS News
Insights
Company Spotlight
A USA-based neuroscience-focused company working towards overcoming the delivery hurdle in large molecule drug development.
Latest News & Features of interest to Lundbeck
Biotechnology
Stalicla, a privately-held Swiss biotech, today announced that Dr Paulo Fontoura will be joining its drug development team as chief scientific and clinical development advisor. 19 September 2024
Pharmaceutical
US clinical stage CNS drug developer Athira Pharma is taking decisive action following the company’s announcement of disappointing data from the Phase II/III LIFT-AD clinical trial of fosgonimeton to treat Alzheimer’s disease (AD). 18 September 2024
Biotechnology
The US Food and Drug Administration (FDA) has approved Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq) for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS), from Swiss pharma giant Roche. 16 September 2024
Pharmaceutical
US pharma major Eli Lilly has announced a $1 billion expansion of its manufacturing site in Limerick, Ireland, to increase production of biologic active ingredients, including those for its recently approved treatment for early symptomatic Alzheimer's disease. 13 September 2024
Biotechnology
US neurological diseases specialist Ovid Therapeutics has announced the promotion of Meg Alexander to president and chief operating officer (COO). 12 September 2024
Biotechnology
Ionis Pharmaceuticals has announced plans to raise $500 million through a public offering. 11 September 2024
Pharmaceutical
The global migraine market in mature economies is projected to grow from $9.2 billion in 2023 to $16.4 billion by 2033, according to a report from GlobalData. 10 September 2024
Biotechnology
Cartesian Therapeutics today announced that the US Food and Drug Administration (FDA) has granted Rare Pediatric Disease designation to Descartes-08 for the treatment of juvenile dermatomyositis (JDM). 9 September 2024
Pharmaceutical
Psyence Biomedical has announced plans to acquire Clairvoyant Therapeutics, a Canadian developer of psilocybin-based treatments. 9 September 2024
Biotechnology
US RNA medicines developer Stoke Therapeutics has announced the appointment of Eric Olson as chief business officer. 7 September 2024
Latest In Brief for Lundbeck
Biotechnology
Sweden-based BioArctic saw its fall 7.5% to 139.90 kronor on Friday, after its announced that its partner, Japan’s Eisa, has updated its revenue outlook for the Alzheimer’s treatment Leqembi (lecanemab) for the 2024 fiscal year (FY), which runs from April 2024 through March 2025. 11 November 2024
Latest CNS Ones To Watch News
CNS Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze